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Background/aim: To evaluate pregnancy-associated plasma protein A (PAPP-A), ischemia-modified albumin (IMA), procalcitonin,
and troponin I levels as diagnostic markers of acute coronary syndrome in patients admitted to the emergency department.
Materials and methods: The serum PAPP-A, IMA, procalcitonin, and troponin I levels were measured in 100 patients with acute
coronary syndrome admitted to the emergency department and 100 healthy control subjects.
Results: Patients with acute coronary syndrome had significantly greater mean serum PAPP-A (patients, 10 ± 10 mIU/L; control
subjects, 6 ± 10 mIU/L; P ≤ 0.001), procalcitonin (patients, 2 ± 10 µg/L; control subjects, 0.4 ± 2 µg/L; P ≤ 0.001), and troponin I
levels (patients, 6 ± 8 µg/L; control subjects, 0.2 ± 0.3 µg/L; P ≤ 0.001) than control subjects. There was no difference in mean IMA
levels between patients and control subjects. There were no significant correlations between PAPP-A levels and IMA, procalcitonin, or
troponin I levels in patients with acute coronary syndrome.
Conclusion: The PAPP-A, procalcitonin, and troponin I levels were increased in patients with acute coronary syndrome. Therefore,
elevated PAPP-A and procalcitonin levels, in addition to troponin I levels, may be useful markers of myocardial injury on admission to
the emergency department.
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1. Introduction
Diagnosis of patients with acute coronary syndrome is
important in the emergency department. Diagnosis usually
is established with clinical findings, electrocardiographic
changes, biochemical markers of myocardial damage,
and myocardial perfusion imaging. There are no ideal
biochemical markers to quantify myocardial damage
early after acute coronary syndrome with high clinical
sensitivity and specificity. Although cardiac troponin levels
are highly sensitive and specific markers for the diagnosis
of myocardial necrosis, troponin may not be detected in
the blood until 6 to 9 h after the onset of chest pain (1).
Therefore, other early markers of myocardial necrosis are
being evaluated.
Pregnancy-associated plasma protein A (PAPP-A),
a metalloproteinase present in the serum of women in
late pregnancy, is a marker of inflammation and plaque
instability (2). PAPP-A is a useful marker for early
detection of acute coronary syndrome and identification
of patients at risk for an acute ischemic cardiac event (3–
* Correspondence: aysegulbayir@hotmail.com

5). Another serum protein, ischemia-modified albumin
(IMA), increases rapidly in acute ischemic coronary
events and may be a sensitive marker for the diagnosis of
myocardial ischemia (6,7).
Procalcitonin, a calcitonin precursor hormone
secreted by the thyroid gland, has high serum levels in
inflammatory conditions. High procalcitonin levels are
correlated with the severity of infections. Follow-up is
an important marker for the diagnosis and treatment of
bacterial sepsis (8). There are few studies about serum
procalcitonin levels in patients with cardiogenic shock
and acute coronary syndrome, and results are conflicting.
Although procalcitonin levels may be increased in patients
with acute coronary syndrome on admission to the hospital,
procalcitonin levels may also be normal in patients who
have uncomplicated acute myocardial infarction (9,10).
A literature review showed no previous study comparing
PAPP-A, IMA, procalcitonin, and troponin I levels on
admission of patients with acute coronary syndrome to the
emergency department.
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We performed the present study to evaluate the
hypothesis that PAPP-A, IMA, and procalcitonin may
be useful in the diagnosis of acute coronary syndrome.
The purpose of this study was to evaluate PAPP-A, IMA,
procalcitonin, and troponin I levels on admission of
patients with acute coronary syndrome to the emergency
department.
2. Materials and methods
Between 1 June 2011 and 31 October 2012, there were
100 patients aged 18 to 80 years who were diagnosed
with acute coronary syndrome (ST-segment elevation
myocardial infarction, non-ST-segment elevation
myocardial infarction, and unstable angina pectoris) at
the Emergency Department of the Faculty of Medicine
of Selçuk University and recruited for the study group.
Ischemic character chest pain, ECG findings (ST elevation
or depression, ST-segment depression, T wave changes,
newly developed left bundle branch block) and high
troponin I level were criteria for the diagnosis of acute
coronary syndrome. Acute coronary syndrome was
diagnosed when the two criteria were positive. A control
group of 100 healthy volunteers aged 18 to 80 years included
individuals recruited from the Emergency Department
who did not have acute coronary syndrome. Patients with
history of heart failure, systemic infection, malignancy,
pregnancy, acute or chronic renal failure, acute or chronic
liver failure, stroke, endocrine disease, oncological disease,
chronic obstructive pulmonary disease, or trauma were
excluded from the control group. Patients were excluded
from the study group if they had a history of severe
systemic disease, stroke, endocrine disorders, chronic
obstructive pulmonary disease, chronic renal failure,
chronic liver disease, acute or chronic infection, sepsis,
trauma, pregnancy, or malignancy. Patients and control
subjects were informed about the study and gave written
informed consent. The study was approved by the Selçuk
University Faculty of Medicine Non-Drug-Using Clinical
Research Ethics Committee (No. 2011/051).
2.1. Study setting
Venous blood samples were taken from patients in the
study group within 6 h after the onset of ischemic chest
pain.
In all subjects, venous blood samples were drawn into
straight jelly tubes during the evaluation in the emergency
department for evaluation of PAPP-A, IMA, procalcitonin,
and troponin I. After 25 min, the samples were centrifuged
at 3000 rpm for 5 min, and sera were stored at –80 °C
until they were thawed to room temperature for testing.
The PAPP-A and procalcitonin levels were determined
from sera with commercially available kits (Roche Cobas
kits, Roche, Japan) and an analyzer (Roche Modular E170
device, Roche) that was calibrated and checked with its
own calibrator and controls.
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The IMA level was measured as the binding capacity of
reduced cobalt to albumin using a rapid colorimetric method
(11). Each serum sample (200 µL ) was added to a glass
tube and mixed with cobalt chloride (0.1% in water; 50 µL;
Merck, Germany). After gentle shaking, the mixture was left
undisturbed for 10 min to ensure sufficient binding of cobalt to
albumin. Dithiothreitol (1.5 mg/µL; 50 µL; Merck) was added
as a coloring agent; a control specimen was prepared for each
sample using distilled water (50 µL) instead of dithiothreitol.
After 2 min, sodium chloride (0.9%; 1 µL) was added to stop
the binding between cobalt and albumin. Absorbance at
470 nm was measured with a spectrophotometer (PerkinElmer
Lambda 25 UV/VIS spectrometer, Lot No: L600000B, Serial
No: 501S10083108, PerkinElmer, USA). Color formation
was compared between specimens with dithiothreitol and
controls, and the results were expressed as absorbance
units. The albumin-adjusted IMA levels were calculated as
previously described and expressed as (individual serum
albumin concentration/median albumin concentration of the
population) × IMA value (12). All samples were measured
during the same laboratory session. The intraassay coefficient
of variation was 7.1%, consistent with information from
Abbot (Japan). Albumin concentrations were determined
with a commercially available kit (Merck) based on the
bromocresol purple method.
2.2. Data analysis
The Shapiro–Wilk test showed that the markers had
nonparametric distributions. The Mann–Whitney test was
used to compare medians. Spearman rank correlation was
used to evaluate the relation between the markers. Data were
reported as mean ± SD. Statistical significance was defined as
P ≤ 0.05.
3. Results
The data related to risk factors of the patient and control
groups are shown in Table 1.
Sixty-four patients with acute coronary syndrome had
ST-segment elevation myocardial infarction (STEMI). In the
acute coronary syndrome group, 31 patients had non-STsegment elevation myocardial infarction (NSTEMI) and 5
patients had unstable angina pectoris (UAP). The mean time
from the beginning of ischemic chest pain until a venous
blood sample was taken in the patients with acute coronary
syndrome was 115 ± 72 min.
The mean serum PAPP-A, procalcitonin, and troponin I
levels of the patients with STEMI were significantly greater
than those of the control group (P < 0.01). The mean serum
PAPP-A, procalcitonin, and troponin I levels of the patients
with NSTEMI were significantly greater than those of the
control group (P < 0.01). A significant difference was not
determined between patients with UAP and the control group
for mean serum PAPP-A, procalcitonin, and troponin I levels
(Table 2).
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Table 1. Risk factors related to acute coronary syndrome in patient and control groups.
Parameter

Acute coronary syndrome

Control

No. of patients

100

100

P*

Age

61 ± 14

64 ± 13

NS

Family history of cardiac disease

32 patients

27 patients

NS

Hypertension

35 patients

31 patients

NS

History of hyperlipidemia

12 patients

8 patients

NS

Diabetes mellitus

15 patients

11 patients

NS

Cigarette smoking

33 patients

25 patients

NS

Sedentary life style

17 patients

14 patients

NS

*NS, Not significant; P > 0.05.

The mean age was similar between patients with acute
coronary syndrome and control subjects (Table 3). The
mean serum PAPP-A, procalcitonin, and troponin I levels
were significantly greater in patients with acute coronary
syndrome than control subjects (Table 3). The mean IMA
level was similar between patients with acute coronary
syndrome and control subjects (Table 3). There were no
significant correlations between PAPP-A levels and IMA,
procalcitonin, or troponin I levels in patients with acute
coronary syndrome.
4. Discussion
The present study showed that PAPP-A, procalcitonin,
and troponin I levels were increased in patients with
acute coronary syndrome (Table 1), consistent with the
hypothesis that these markers may be useful diagnostically.
However, IMA was not increased in patients with acute
coronary syndrome (Table 1).
The present study confirmed previously reported
findings that PAPP-A may be a useful diagnostic marker
for acute coronary syndrome. In a previous study that
compared PAPP-A levels with troponin I and creatine
kinase-MB fraction in the early diagnosis of acute coronary
syndrome, PAPP-A had high diagnostic sensitivity (90%)
and specificity (85%) (2). Furthermore, PAPP-A was a
useful marker in the clinical evaluation of patients with
acute coronary syndrome (4). In addition, studies to
evaluate PAPP-A for risk assessment and prognosis showed
that PAPP-A was associated with recurrent cardiovascular
events and mortality in patients with STEMI and NSTEMI
(13–15). In patients with ischemic cardiac chest pain, high
PAPP-A levels may be helpful in predicting long-term
cardiovascular mortality (3).
Although PAPP-A, procalcitonin, and troponin I
levels were all elevated in patients with acute coronary
syndrome (Table 1), no correlation was evident between
PAPP-A levels and IMA, procalcitonin, or troponin I levels

in patients with acute coronary syndrome. Therefore,
PAPP-A levels may be a useful indicator of myocardial
necrosis for the diagnosis of acute coronary syndrome but
may follow a different time course than procalcitonin or
troponin I.
In the present study, mean IMA levels were similar
between patients who had acute coronary syndrome and
control subjects. This suggests that IMA levels may not be
useful as a diagnostic indicator in the differential diagnosis
of acute coronary syndrome in the emergency department.
Previous studies reported that IMA had good accuracy
(66% to 95%) but low specificity (13% to 45%) for the
diagnosis of patients with acute coronary syndrome (16–
18), although IMA may not be used to reliably exclude the
diagnosis of acute coronary syndrome in the emergency
department (19,20). IMA may be a guide as to whether to
perform further investigation for acute coronary syndrome
in patients admitted to the emergency department with
chest pain, analogous to D-dimer testing in the diagnostic
algorithm for pulmonary embolism (21,22). In addition,
IMA levels may not distinguish between patients who
have either ST-segment elevation myocardial infarction or
unstable angina pectoris (23).
In the present study, procalcitonin levels were
significantly higher in patients with acute coronary
syndrome on admission to the emergency department
than healthy control subjects (Table 1), but there was no
correlation between procalcitonin and troponin I levels.
Therefore, elevated procalcitonin levels in patients with
acute coronary syndrome on admission to the emergency
department may be a supportive diagnostic indicator,
and high procalcitonin levels may

reflect the severity of
the inflammatory process in patients with acute coronary
syndrome.
Few previous studies have been performed to evaluate
procalcitonin levels in patients with acute coronary syndrome,
and conflicting results were reported. In a study of patients
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Table 2. Serum markers in patients with STEMI, NSTEMI, and
UAP and control subjects.*

Table 3. Serum markers in patients with acute coronary
syndrome and control subjects.*

Parameter

STEMI

Control

Parameter

Control

No. of patients

64

100

Acute coronary
syndrome

PAPP-A (mIU/L)

12.5 ± 9

6 ± 10

0.001

No. of patients

100

100

IMA (U/mL)

1.2 ± 0.9

1.1 ± 0.2

NS

Age

61 ± 14

64 ± 13

NS

Procalcitonin (µg/L)

2.5 ± 2

0.4 ± 2

0.001

Sex (men/women)

65/25

53/47

NS

Troponin I (µg/L)

7.8 ± 4

0.2 ± 0.3

0.001

PAPP-A (mIU/L)

10 ± 10

6 ± 10

0.001

NSTEMI

Control

P†

IMA (U/mL)

1.1 ± 0.7

1.1 ± 0.2

NS

No. of patients

31

100

Procalcitonin (µg/L)

2 ± 10

0.4 ± 2

0.001

PAPP-A (mIU/L)

10 ± 4.5

6 ± 10

0.001

Troponin I (µg/L)

6±8

0.2 ± 0.3

0.001

IMA (U/mL)

1.1 ± 0.4

1.1 ± 0.2

NS

Procalcitonin (µg/L)

2.2 ± 1.8

0.4 ± 2

0.001

Troponin I (µg/L)

6.2 ± 5

0.2 ± 0.3

0.001

UAP

Control

P†

No. of patients

5

100

PAPP-A (mIU/L)

10.5 ± 7

6 ± 10

0.001

IMA (U/mL)

1.0 ± 0.4

1.1 ± 0.2

NS

Procalcitonin (µg/L)

0.5 ± 2.2

0.4 ± 2

NS

Troponin I (µg/L)

0.2 ± 0.1

0.2 ± 0.3

NS

P†

*Data are expressed as number or mean ± SD. STEMI, ST elevation
myocardial infraction; NSTEMI, non-ST elevation myocardial
infraction; UAP, unstable angina pectoris; PAPP-A, pregnancyassociated plasma protein A; IMA, ischemia-modified albumin.
† NS, Not significant; P > 0.05.

admitted to the hospital with acute myocardial infarction,
serum procalcitonin levels had increased before troponin I
and creatine kinase-MB fraction levels, and procalcitonin
was considered a new and precise indicator for the diagnosis
of acute myocardial infarction (9). However, another study
concluded that procalcitonin levels had increased only in
patients with cardiogenic shock from acute myocardial
infarction and in few patients with uncomplicated STEMI;
indicators of inflammation such as C-reactive protein
were considered more valuable and were not correlated
with procalcitonin levels (24). Nevertheless, elevated
procalcitonin levels on admission may be associated with
short- and long-term mortality in patients who have acute

P†

*Data are expressed as number or mean ± SD. PAPP-A,
Pregnancy-associated plasma protein A; IMA, ischemiamodified albumin. † NS, Not significant; P > 0.05.

coronary syndrome without signs of infection and who are
followed in a coronary intensive care unit, and procalcitonin
levels potentially may be an indicator to identify patients at
high risk of mortality from acute coronary syndrome (25).
Limitations of the present study include the
unavailability of information about time between onset of
symptoms and admission to the emergency department for
patients with acute coronary syndrome; this information
may have improved the potential for identifying a
correlation between the measured markers. In addition,
only one blood sample was available for each patient,
which precluded an evaluation of the time dependence and
peak level of the markers. Furthermore, the PAPP-A, IMA,
procalcitonin, and troponin I levels were evaluated only
for use in emergency differential diagnosis, and follow-up
information was not available to evaluate these markers for
prediction of prognosis. Nevertheless, the present results
justify further study to evaluate these important issues.
In summary, the present results provide evidence
that PAPP-A, procalcitonin, and troponin I levels may be
useful, but IMA level may not be helpful, in the diagnosis
of acute coronary syndrome in patients admitted to the
emergency department.
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